Literature DB >> 27377904

RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Sinead Toomey1, Alex J Eustace2, Laura B Pritzker1, Ken P H Pritzker1, Joanna Fay1, Anthony O'Grady1, Robert Cummins1, Liam Grogan1, John Kennedy1, Darran O'Connor1, Leonie Young1, Elaine W Kay1, Norma O'Donovan1, William M Gallagher1, Roshni Kalachand1, John Crown1, Bryan T Hennessy1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27377904      PMCID: PMC5017949          DOI: 10.1093/jnci/djw111

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  4 in total

1.  RNA Disruption and Drug Response in Breast Cancer Primary Systemic Therapy.

Authors:  Kenneth Pritzker; Laura Pritzker; Daniele Generali; Alberto Bottini; Maria Rosa Cappelletti; Baoqing Guo; Amadeo Parissenti; Maureen Trudeau
Journal:  J Natl Cancer Inst Monogr       Date:  2015-05

2.  Tumor RNA disruption predicts survival benefit from breast cancer chemotherapy.

Authors:  Amadeo M Parissenti; Baoqing Guo; Laura B Pritzker; Kenneth P H Pritzker; Xiaohui Wang; Mu Zhu; Lois E Shepherd; Maureen E Trudeau
Journal:  Breast Cancer Res Treat       Date:  2015-07-25       Impact factor: 4.872

3.  Association of low tumor RNA integrity with response to chemotherapy in breast cancer patients.

Authors:  Amadeo M Parissenti; Judy-Anne W Chapman; Harriette J Kahn; Baoqing Guo; Lei Han; Patti O'Brien; Mark P Clemons; Roberta Jong; Rebecca Dent; Barbara Fitzgerald; Kathleen I Pritchard; Lois E Shepherd; Maureen E Trudeau
Journal:  Breast Cancer Res Treat       Date:  2010-01       Impact factor: 4.872

4.  Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: proof from the "biological window therapy".

Authors:  Chiara Foroni; Manuela Milan; Carla Strina; Mariarosa Cappelletti; Claudia Fumarola; Mara Bonelli; Ramona Bertoni; Giuseppina Ferrero; Mara Maldotti; Elena Takano; Daniele Andreis; Sergio Venturini; Giulia Brugnoli; Pier Giorgio Petronini; Vanessa Zanoni; Laura Pritzker; Kenneth Pritzker; Amadeo Parissenti; Daniele Santini; Stephen B Fox; Alberto Bottini; Daniele Generali
Journal:  Breast Cancer Res Treat       Date:  2014-01-28       Impact factor: 4.872

  4 in total
  4 in total

1.  The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancer.

Authors:  J Fay; S Toomey; A J Eustace; S F Madden; D M Collins; E W Kay; K M Sheehan; S Furney; B Moran; A Fagan; P G Morris; A Teiserskiene; A D Hill; L Grogan; J M Walshe; O Breathnach; C Power; D Duke; K Egan; W M Gallagher; N O'Donovan; J Crown; B T Hennessy
Journal:  Breast Cancer Res Treat       Date:  2021-05-13       Impact factor: 4.872

Review 2.  Predictors of Neoadjuvant Chemotherapy Response in Breast Cancer: A Review.

Authors:  Weilin Xu; Xiu Chen; Fei Deng; Jian Zhang; Wei Zhang; Jinhai Tang
Journal:  Onco Targets Ther       Date:  2020-06-22       Impact factor: 4.147

3.  RNA disruption indicates CHOP therapy efficacy in canine lymphoma.

Authors:  Amadeo M Parissenti; Laura B Pritzker; Baoqing Guo; Rashmi Narendrula; Shirly Xiaohui Wang; Lin Laura Lin; Jingchun Pei; Karolina Skowronski; Dorothee Bienzle; J Paul Woods; Kenneth P H Pritzker; Brenda L Coomber
Journal:  BMC Vet Res       Date:  2019-12-16       Impact factor: 2.741

4.  Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer.

Authors:  Denis M Collins; Stephen F Madden; Nicola Gaynor; Dalal AlSultan; Marion Le Gal; Alex J Eustace; Kathy A Gately; Clare Hughes; Anthony M Davies; Thamir Mahgoub; Jo Ballot; Sinead Toomey; Darran P O'Connor; William M Gallagher; Frankie A Holmes; Virginia Espina; Lance Liotta; Bryan T Hennessy; Kenneth J O'Byrne; Max Hasmann; Birgit Bossenmaier; Norma O'Donovan; John Crown
Journal:  Clin Cancer Res       Date:  2020-10-29       Impact factor: 13.801

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.